# SPINRAZA Clinical Trial Data Overview
Keywords: SMA, SPINRAZA, clinical trials, motor function, HFMSE, 6MWT, pre-symptomatic treatment, NURTURE study, WHO motor milestones

> This page provides an overview of SPINRAZA clinical trial data, highlighting its impact on motor function development in infants with SMA treated pre-symptomatically, and includes detailed study design and outcomes.

## Details
- [Clinical Trial Data](#): Overview of SPINRAZA's clinical trial results, focusing on motor function improvements in SMA patients.
- [NURTURE Study Design](#): Phase II open-label study evaluating SPINRAZA in pre-symptomatic SMA infants, with over 8 years of follow-up data.
- [Motor Function Development](#): Near-normal motor function development achieved in pre-symptomatically treated SMA patients.
- [WHO Motor Milestones](#): Positive outcomes in achieving WHO motor milestones, including sitting, standing, and walking.
- [HFMSE Scores](#): Progressive improvement in motor function over 8 years, assessed via the Hammersmith Functional Motor Scale Expanded.
- [6MWT Results](#): Continuous increase in walking distance over 8 years, measured by the 6-Minute Walk Test.
- [Definitions: HFMSE and 6MWT](#): Explanation of the HFMSE scale and 6-Minute Walk Test used to evaluate motor function.
- [Adverse Event Reporting](#): Instructions for reporting adverse events in the UK and Ireland, including contact details.